Given the fact that patients undergoing allogeneic stem cell transplantation are deficient in both cellular and humoral immunity for a prolonged period and are susceptible to a number of endogenous and exogenous viral infections during this period, there is scanty data on the incidence of enterovirus infections in this setting. Anecdotal reports have implicated that enteroviruses might be responsible for serious complications in the post transplant period. [4] [5] [6] [7] [8] Some stool surveillance studies have reported on the isolation of these viruses in post transplant patients with diarrhoea, but none have investigated the incidence and outcome of enterovirus infections in a comprehensive manner. [9] [10] [11] Tcell depletion of the graft results in an increase in the incidence of several viral infections, but whether the same is true for enterovirus infections is not known.
We report the incidence and outcome of enterovirus infections with respect to the immune reconstitution in 64 adult patients receiving T-cell-depleted grafts following both conventional and reduced-intensity conditioning (RIC).
Patients and methods
We evaluated 64 T-cell-depleted allograft recipients, who were treated in the BMT unit at Birmingham Heartlands Hospital between May 1997 and September 2001, for evidence of enterovirus infections. All the patients were nursed in single rooms with high-efficiency particulate air (HEPA) filters.
Conditioning treatment and T-cell depletion
Conventional conditioning consisted of cyclophosphamide or etoposide and total body irradiation or busulphan. The RIC schedule consisted of fludarabine and melphalan. Tcell depletion was carried out with Campath (anti-CD52) antibodies (Therapeutic Antibody Centre, Oxford) in vivo or in vitro. All patients also received cyclosporin A as graftversus-host disease (GVHD) prophylaxis from day À1.
Supportive care
Antimicrobial prophylaxis consisted of oral fluconazole, ciprofloxacin and oral aciclovir from the beginning of conditioning treatment until engraftment. Oral cotrimoxazole was initiated when the neutrophil count was greater than 1.0 Â 10 9 /l. Metronidazole 400 mg thrice daily was started from the day of transplant to engraftment for anaerobic decontamination, as a part of GVHD prophylaxis.
Patients at risk of CMV disease (recipient or donor positive for CMV IgG) received pre-emptive therapy with ganciclovir and/or foscarnet, based on a PCR assay. 9 CMV sero-negative patients received blood products from CMV sero-negative donors. None of the patients received prophylactic intravenous immunoglobulins (IVIg).
Study design
Stool, urine and throat samples were examined by virus culture from all patients prior to transplant, and weekly to fortnightly thereafter to 180 days post transplant. In addition, the stool and urine samples were also examined by electron microscopy. After 180 days post transplant, only relevant samples from symptomatic patients were examined. Tissue samples from liver, lungs or gut obtained ante or postmortem were examined by EM and culture.
Laboratory methods. For EM, a 50% v/v suspension of each faecal sample was prepared in phosphate-buffered saline, and placed on EM grids with strengthened formvar membranes. The grids were stained with 2.5% phosphotungstic acid and examined using a Jeol 100CX electron microscope with an accelerating voltage of 80 kV. For culture, 0.2 ml of the supernatant prepared from centrifugation of a 10% v/v suspension of faeces or urine in virus transport medium was added to monolayers of Rhesus monkey kidney and Hep 2 and human fibroblast cell lines. The cells were incubated at 331C for 14 days and examined thrice weekly for cytopathic effects. Enteroviruses were typed using pooled fluorescein-conjugated monoclonal antibodies (Chemicon International Inc., Temecula, CA, USA). In addition, cerebrospinal fluid and other relevant sterile body fluid samples were examined by an RT-PCRbased assay for the presence of enterovirus, as previously described. 12 Specimens for bacteriological and fungal investigations were processed using standard methods of microscopy, culture and sensitivity testing.
Isolation of enteroviruses from any surveillance site was termed as enterovirus infection. Enterovirus disease was defined as definite on demonstration of enteroviruses from a tissue site, and/or detection in the CSF or other sterile body fluids with clinical illness attributable to enteroviruses in the absence of other pathogens. If the viruses were isolated from surveillance samples only, in the presence of a clinical illness explainable by enterovirus infections and not attributable to any other pathogen, this was defined as probable enterovirus disease. Documented infections at other sites were also noted. Co-pathogen was defined as any organism isolated from within 2 weeks before or after detection of enteroviruses or onset of enterovirus-associated symptoms. GVHD was graded according to standard criteria.
The absolute lymphocyte count (ALC) was noted at least once in every 4 weeks following discharge for the first 6 months. ALC was also recorded at the first detection of an enterovirus isolate. The CD4 þ and CD8 þ T-cell counts (since August 1999) were measured every 6-8 weeks post transplant. Immunoglobulin levels (IgG and IgA) were also measured every 3 months for the first year following the transplantation. For statistical analysis, the median CD4 þ , ALC, IgG and IgA levels between 100 and 180 days post transplant were calculated, if more than one set of values were available during that period.
Statistical methods
Univariate P-values and odds ratios were calculated from 2 Â 2 contingency tables using Epi info version 6 (CDC, Atlanta). The continuous variables were compared using Mann-Whitney's nonparametric method. The probability of various events was examined by the Kaplan-Meier method and the groups were compared using the log-rank test.
Results

Incidence of enterovirus infection
Enteroviruses were isolated in seven out of 64 patients (10.4%) at a median of 146 days (range 25-796), with an actuarial probability of 14% (95% CI 4-24). Two patients had multiple episodes of enterovirus infection. Coxsackie B was isolated in three episodes with poliovirus type 1 and an echovirus in one episode each. The enteroviruses isolated from the other four episodes were not serotyped. Enteroviruses were isolated from the throat sample in five episodes and from stool in the other four. The median duration of virus excretion was 2 weeks (range 1-4 weeks). The characteristics of the patients developing enterovirus infections have been detailed in Table 1 .
Outcome of enterovirus infections
Symptomatic illness attributable to enteroviruses was documented in four patients ( Table 2 ). All had upper respiratory illness with systemic symptoms. One patient (patient 6) had protracted myalgia, weakness and fatigue following an enterovirus infection for which no other cause was identified. Patient 3 had coxsackie B virus isolated from a sputum sample during a respiratory illness, which progressed to severe pneumonia, and CMV was subsequently detected in a bronchial lavage sample by PCR. CMV was not detected in blood samples and tissue specimens were not available. This patient improved following mechanical ventilation, IVIg and ganciclovir therapy. Another patient (patient 2) had an enterovirus isolated from stool sample with concurrent gut GVHD, 7 days before she succumbed to a fungal pneumonia. She also had an episode of seizure at the same time, but the CSF was negative for enteroviruses by RT-PCR and culture. Isolation of enteroviruses from the stool was not associated with diarrhoeal illness in any of the other patients. Thus, four episodes of probable enterovirus Enterovirus infection in transplant recipients S Chakrabarti et al disease were documented without any mortality directly attributable to enteroviruses. The only patient (patient 4) who had asymptomatic poliovirus type 1 infection was reported to be in contact with his child, who was receiving live polio vaccination during that period. Four of the seven patients had other viruses isolated at different time-points post transplant and not as a co-pathogen with enteroviruses (Table 2) . Patient 2 had CMV isolated concomitantly as described above, and patient 6 had HSV isolated from oral swabs during the second episode of enterovirus infection. The nonrelapse mortality and overall survival at 3 years among patients developing enterovirus infections were 28.6 and 42.8%, respectively, compared to 23.7 and 60.8% in those not developing these infections (P-values ¼ 0.8 and 0.5, respectively).
Relationship to immune reconstitution
The ALC was available in all patients in both groups alive beyond 100 days. The other immunological parameters were available in five patients with enterovirus infections and 45 patients without enterovirus infection. The relationship between immune reconstitution and development of enterovirus infections is shown in Table 3 . The ALC, CD4 þ T-cell count and the IgG and IgA levels between 100 and 180 days post transplant were similar in patients with or without enterovirus infections. However, it is worth noting that the mean IgG levels were in the normal range and the IgA levels were low normal in both groups. Lymphocytopenia, both absolute and CD4 þ T cells, was documented in both groups.
Risk factors for enterovirus infections
There was no influence of patient age, gender or underlying disease on the isolation of enteroviruses. In addition, there was no impact of the dose and mode of the use of Campath-1H on the isolation of enteroviruses, with 3/33 patients receiving Campath-1H in vitro developing enterovirus infections, compared to 4/31 in those receiving Campath-1H in vivo (Table 1) .
Patients undergoing unrelated donor transplantation were at a greater risk of enterovirus infections (5/24, probability 28%, 95% CI 6-50) than related donors (2/40, probability 6.9%, 95% CI 0-14, log rank P ¼ 0.02, Figure 1 ). Enteroviruses tended to be more frequent in patients undergoing conventional conditioning (6/41 vs 1/ 23 in patients receiving RIC, P ¼ 0.2). Among the recipients of conventional conditioning, enteroviruses were isolated only in patients receiving TBI. Overall, there was a similar trend towards more enterovirus infections in patients receiving TBI (6/37, compared to 1/27 in patients receiving non-TBI-based conditioning, P ¼ 0.18).
Discussion
Enteroviruses have been reported to cause fatal complications following allogeneic transplantation. [4] [5] [6] [7] [8] [9] However, the true impact of infections with enteroviruses in this setting can be estimated only by prospective surveillance studies. Several stool surveillance studies have reported on the isolation of enteroviruses and often implicated them as possible pathogens or co-pathogens in diarrhoeal or respiratory illnesses. [9] [10] [11] It is worth noting that although enteroviruses are usually transmitted via the faeco-oral route, transmission via respiratory route is also possible. 1 Hence, a comprehensive surveillance should include throat specimens and blood or body fluids from symptomatic sites as well, as was carried out in this study.
The overall incidence of enterovirus infections was 10% in this adult cohort of T-cell-depleted transplant recipients. Four of the seven infected patients had symptomatic infections or probable enterovirus disease. All had upper respiratory illnesses, which were often protracted. One patient experienced prolonged myalgia and fatigue even after cessation of viral isolation, very similar to the chronic fatigue syndrome described following enterovirus infections. 1 Coxsackie B virus was isolated from the sputum sample of one patient who progressed to serious but nonfatal pneumonic illness, who subsequently had CMV isolated from bronchial lavage sample. The exact contribution of coxsackie B virus and CMV in the genesis of pneumonia was not certain. Although the stool surveillance studies have often implicated enteroviruses, namely Enterovirus infection in transplant recipients S Chakrabarti et al coxsackie and echoviruses as a causative agent for post transplant diarrhoea, we did not find such an association. [8] [9] [10] [11] The only patient who had enterovirus isolated from stool samples during a diarrhoeal episode had GVHD of the gut as well and the role of enterovirus in causing diarrhoea was not clear. 13 The more serious complications of enterovirus infections, such as CNS and cardiac involvement, were not documented in any of the patients. All the CSF, pericardial and pleural fluids obtained during this period were subjected to viral culture and RT-PCR, but no enteroviruses were detected.
Enteroviruses are generally community-acquired and, although persistence of viral RNA has been demonstrated in chronic medical conditions, 14 there is no evidence to suggest that these viruses can establish latency such as CMV or EBV to reactivate during severe immunosuppression. [14] [15] [16] Enteroviruses have been reported to cause protracted and often fatal illnesses in agammaglobulinemic individuals, the humoral immunity being serotype-specific. 1, 16 The role of cellular immunity in enterovirus infections is not defined, but might play a role in the containment of the virus during early phase of the infection. 17 Unlike most other viral infections we have previously reported, where correlations between the viral infection and the degree of T-cell depletion and lymphocyte reconstitution were established, [18] [19] [20] [21] we did not find any correlation between the extent of T-cell depletion, total and CD4 þ lymphocyte recovery and immunoglobulin subtype levels and the occurrence of enterovirus infections. We identified unrelated donor transplantation as a risk factor for enterovirus infections. Immune reconstitution has been reported to be delayed following T-cell-depleted transplantation from matched unrelated graft compared to matched sibling grafts, and could account for this association. 22 However, this needs to be confirmed in larger cohorts. There was a trend towards less enterovirus infections in patients receiving RIC. Although six out of seven enterovirus infections were documented in patients receiving TBI, the study probably lacked the statistical power to identify the association between conditioning therapy and post transplant enterovirus infection. In animal models, TBI has been associated with impaired humoral immune response possibly related partly to functional Figure 1 The incidence of enterovirus infection following T-cell-depleted allograft in relation to the donor type (related vs unrelated).
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S Chakrabarti et al hyposplenism. 23, 24 Further larger studies are needed to delineate any role of conditioning, particularly TBI on the risk of acquisition of enterovirus infection.
Group A coxsackieviruses do not grow readily in conventional cell culture medium. 1 Thus, the incidence of enterovirus infections might have been higher if surveillance samples were subjected to more sensitive assays such as RT-PCR, 12, 25 but the fact remains that enteroviruses in this study were rarely associated in life-threatening complications. There are a number of possible explanations for these findings. Firstly, recovery of absolute IgG levels was prompt in these patients and could have prevented serious enterovirus infections. Secondly, the role of T lymphocytes in causing enterovirus-related tissue damage, particularly cardiac, has been documented in animal studies. In a mouse model, tissue damage due coxsackievirus B4 was found to be mediated by CD4 þ T cells. 17, 26 In the setting of T-cell-depleted transplantation, slower recovery of T lymphocytes, particularly the CD4 þ subset, might have helped in attenuation of the severity of these infections. The absence of GVHD due to T-cell depletion might have had a beneficial impact on the outcome of enterovirus infections, as it has been shown that proinflammatory cytokines are involved in the progression of enterovirus-mediated tissue damage 17 . Finally, B lymphocytes are supposed to be early targets of enteroviruses and could mediate its propagation and dissemination. 27 Campath-1H effectively depletes B lymphocytes. 28 It might be speculated that, similar to EBV infections, a possible reason for lower infection rates and lack of prolonged persistence of the virus might be due to B lymphocytopenia related to the use of Campath-1H. It would be interesting to note the incidence and outcome of enterovirus infections following other modalities of T-cell depletion where B lymphocytes are not depleted from the graft.
Finally, there is no established treatment for enterovirus infections. Intravenous Ig (IVIg) have been used for patients with agammaglobulinemia, but, as mentioned previously, the antibody response is serotype specific and IVIg may not always be helpful. 29, 30 Pleconaril, a new oral antiviral drug with specificity for picornaviruses, has shown promise in phase 1 trials and might be considered for highrisk patients, 31 ,32 such as those with major organ involvement or if the infection occurs in the presence of GVHD.
In conclusion, enterovirus infections were documented in 10% of patients undergoing T-cell-depleted transplantation, accounting for symptomatic episodes in half of them. Severe enterovirus disease or death was uncommon in this cohort. There was no correlation between enterovirus infections and lymphocyte recovery or Ig levels. Unrelated donor graft recipients were at the highest risk of infections with enteroviruses. Further studies using more sensitive detection methods are needed to define the impact of enteroviruses in different allograft settings.
